NEWS
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGen Biotech (Nasdaq: NKGN) announced that CEO Paul Y. Song, MD, will present updated Phase 1 data on their SNK02 allogeneic NK cell therapy at the 6th Annual Allogeneic Cell Therapies Summit, June 10-12, 2024, in Boston, MA. The presentation, scheduled for June 12, will highlight the company's cryopreserved allogeneic NK cell therapy platform and the initial Phase 1 results for advanced refractory solid tumors. Dr. Song will discuss the potential benefits of eliminating pre-treatment lymphodepletion, which may reduce toxicity and preserve immune function. Further, the presentation will explore unexpected findings from the SNK02 trial that suggest its use beyond cancer treatment. A copy of the presentation will be available on the company's website post-event.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1259Followers
76Following
8848Visitors
Follow